Immuneering's Atebimetinib Shows 17.3-Month Survival in Pancreatic Cancer Trial — Immuneering Corporation

Event summary

Immuneering reported a 17.3-month median overall survival in first-line metastatic pancreatic cancer patients treated with atebimetinib plus chemotherapy in a Phase 2a trial.
Full data from 55 patients will be presented at the ASCO Annual Meeting on June 1, 2026.
Only two Grade 3 or higher treatment-related adverse events were observed in ≥10% of patients, both chemotherapy-related.
The company's Phase 3 MAPKeeper 301 trial is currently recruiting and on track to dose the first patient in mid-2026.

The big picture

Immuneering's Phase 2a trial results for atebimetinib in pancreatic cancer represent a significant milestone in the development of targeted therapies for this aggressive disease. The 17.3-month median overall survival is notable, especially given the historically poor prognosis for metastatic pancreatic cancer. The data supports the company's pivot to a randomized Phase 3 trial, which could validate atebimetinib as a potential new standard of care if successful. The focus on tolerability and patient quality of life also aligns with broader industry trends toward therapies that extend survival while maintaining functional status.

What we're watching

Trial Execution: Whether the Phase 3 MAPKeeper 301 trial can replicate the Phase 2a results and meet its recruitment timelines.
Regulatory Pathway: The pace at which Immuneering can advance atebimetinib through regulatory approvals given the promising Phase 2a data.
Competitive Landscape: How Immuneering's results position atebimetinib against existing and emerging therapies for metastatic pancreatic cancer.